Clinical safety of ranibizumab in age-related macular degeneration.
about
Comparative safety and tolerability of anti-VEGF therapy in age-related macular degenerationVisual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases.Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients.Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.Critical appraisal of ranibizumab in the treatment of diabetic macular edema.Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabTopical ranibizumab as a treatment of corneal neovascularizationCombination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial.Recent developments in the treatment of age-related macular degeneration.Emerging therapeutic approaches in the management of retinal angiogenesis and edema.Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literatureIntravitreal aflibercept for neovascular age-related macular degeneration.Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death.Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD.Ranibizumab: a medical treatment that requires surgical administration.Evaluation of retrobulbar blood flow by color doppler ultrasonography after intravitreal ranibizumab injection in patients with neovascular age-related macular degeneration.
P2860
Q26852289-F38C576A-56AB-4DD5-9749-29CFA21859F1Q33686810-D1EB8983-23B2-4644-8739-60FEB681C7A8Q34325608-9B55E901-A36B-4984-BE27-4EC92D1607F8Q34658699-E965715B-6A26-4238-A52B-2102B9F739B3Q34803171-EC4A2DFE-78D7-4818-9583-C4C476B2527AQ35226694-B32DD063-C911-482A-824F-A4B621663267Q37577521-CA43EEE2-7AA4-4A8A-B830-3DCD4A860D98Q37613791-08EED876-705A-46E1-914B-F619390758FFQ37679956-6944191D-0B02-4DF7-9A71-B04FA92336C3Q37822290-C6A3C375-9393-40AE-8B4E-E98F418D8F90Q38003860-F55B85B7-E29F-42DD-B059-3A4AF0725305Q38094076-2BB29724-FBC6-4A95-9B5C-04FC382ADEC7Q38110731-20DDEF86-0C3E-4949-9111-E632A46447CDQ39466620-19D1B795-859C-4D09-A1E3-BAE4147AF224Q39491363-56A0E7D6-6461-4404-ADC5-5BCDF534DB02Q42729433-0B160CFD-DA4B-4D16-871C-7F84AB03ED72Q42909974-C1341F2D-4FB2-43AC-956F-FD6AE79F0F0AQ44252123-BD23FD77-7C95-4AAC-81A5-3CF2B72B7569
P2860
Clinical safety of ranibizumab in age-related macular degeneration.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical safety of ranibizumab in age-related macular degeneration.
@en
Clinical safety of ranibizumab in age-related macular degeneration.
@nl
type
label
Clinical safety of ranibizumab in age-related macular degeneration.
@en
Clinical safety of ranibizumab in age-related macular degeneration.
@nl
prefLabel
Clinical safety of ranibizumab in age-related macular degeneration.
@en
Clinical safety of ranibizumab in age-related macular degeneration.
@nl
P2860
P1476
Clinical safety of ranibizumab in age-related macular degeneration.
@en
P2860
P304
P356
10.1517/14740330903418422
P407
P577
2010-01-01T00:00:00Z